Scientific Sessions 2024  /  Annual Lipid Updates - 2024  /  New Frontiers in Triglyceride Lowering
Logo

American Heart Association

  191
  0

Final ID:

New Frontiers in Triglyceride Lowering

  • Tokgozoglu, Lale  ( HACETTEPE UNIVERSITY , Ankara , Turkey )
  • Remaley, Alan T  ( NIH , Bethesda , Maryland , United States )
  • Cariou, Bertrand  ( CHU Nantes , Nantes Cedex 1 , France )
  • Hudgins, Lisa  ( The Rogosin Institute , New York , New York , United States )
    • Author Disclosures:
    Lale Tokgozoglu: DO have relevant financial relationships ; Advisor:Abbott:Active (exists now) ; Advisor:MSD:Active (exists now) ; Advisor:Novartis:Active (exists now) ; Advisor:EliLilly:Active (exists now) ; Advisor:NovoNordisk:Active (exists now) ; Speaker:Ultragenyx:Active (exists now) ; Speaker:Sanofi:Active (exists now) ; Speaker:NovoNordisk:Active (exists now) ; Speaker:Novartis:Active (exists now) ; Speaker:MSD:Active (exists now) ; Speaker:Daiichi Sankyo:Active (exists now) ; Advisor:Daiichi Sankyo:Active (exists now) ; Advisor:Sanofi:Active (exists now) ; Speaker:Amarin:Active (exists now) ; Speaker:Amgen:Active (exists now) | Alan T Remaley: No Answer | Bertrand Cariou: DO have relevant financial relationships ; Advisor:Novartis:Active (exists now) ; Advisor:Ultragenyx:Past (completed) ; Speaker:Amgen:Past (completed) ; Advisor:MSD:Active (exists now) ; Advisor:Eli Lilly:Active (exists now) ; Advisor:Novo-Nordisk:Active (exists now) ; Speaker:Astra-Zeneca:Past (completed) ; Speaker:Sanofi:Active (exists now) ; Research Funding (PI or named investigator):Sanofi:Past (completed) | Lisa Hudgins: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Annual Lipid Updates - 2024

Sunday, 11/17/2024 , 08:00AM - 09:15AM

Cardiovascular Seminar

More abstracts on this topic:
Lipoprotein(a): Modifiable Risk Factor, Update in Targeted Therapies

Yeang Calvin, Bhatia Harpreet, Mehta Anurag

The Role of Advanced Lipid Testing in 2024

Shapiro Michael, Gianos Eugenia, Taub Pam, Wilkinson Michael

More abstracts from these authors:
Targeting triglyceride-rich lipoproteins: Beyond fibrates and fish oils

Cariou Bertrand, Hobbs Helen, Boren Jan

Long-term Efficacy and Safety of Lerodalcibep in the Open-label 72-week Extension Study of Subjects Previously on Inclisiran or Lerodalcibep in the LIBerate-VI Trial

Asprusten Emil, Licka Manuela, Cariou Bertrand, Vest Jeff, Kallend David, Stein Evan

You have to be authorized to contact abstract author. Please, Login
Not Available